Erimos Pharmaceuticals, which has its research facility at N.C. State’s Centennial campus, has launched a Phase 1 clinical trial of its lead drug candidate EM-1421.
The drug is seen as a treatment for tumors that are not responsive to conventional therapy.
Erimos, which was founded in 2000, has licensed technology from Johns Hopkins University.
The trial is designed to determine safety and maximum tolerated dose of the drug as well as its effectiveness. Some 30 patients are enrolled. EM-1421 is derived from a desert plant.